Biblio Discovery — Demo Discovery Service

20 results for "Atz, Kenneth"

Showing 1–20 · 0.73 seconds · RSS

  1. Journal Article Full text

    Exploring protein–ligand binding affinity prediction with electron density-based geometric deep learning

    Isert, Clemens; Atz, Kenneth; Riniker, Sereina et al.

    RSC Adv · 2024 · English · PubMed Central

    Rational structure-based drug design relies on accurate predictions of protein–ligand binding affinity from structural molecular information. Although deep learning-based methods for predicting binding affinity have shown promise in computational drug design, certain approaches have faced criticism…

  2. Journal Article Full text

    QMugs, quantum mechanical properties of drug-like molecules

    Isert, Clemens; Atz, Kenneth; Jiménez-Luna, José et al.

    Sci Data · 2022 · English · PubMed Central

    Machine learning approaches in drug discovery, as well as in other areas of the chemical sciences, benefit from curated datasets of physical molecular properties. However, there currently is a lack of data collections featuring large bioactive molecules alongside first-principle quantum chemical…

  3. Journal Article Full text

    NMR pseudocontact shifts in a symmetric protein homotrimer

    Müntener, Thomas; Böhm, Raphael; Atz, Kenneth et al.

    J Biomol NMR · 2020 · English · PubMed Central

    NMR pseudocontact shifts are a valuable tool for structural and functional studies of proteins. Protein multimers mediate key functional roles in biology, but methods for their study by pseudocontact shifts are so far not available. Paramagnetic tags attached to identical subunits in multimeric…

  4. Journal Article Full text

    Δ-Quantum machine-learning for medicinal chemistry

    Atz, Kenneth; Isert, Clemens; Böcker, Markus N. A. et al.

    Phys Chem Chem Phys · 2022 · English · PubMed Central

    Many molecular design tasks benefit from fast and accurate calculations of quantum-mechanical (QM) properties. However, the computational cost of QM methods applied to drug-like molecules currently renders large-scale applications of quantum chemistry challenging. Aiming to mitigate this problem…

  5. Journal Article Full text

    Protein Binding Site Representation in Latent Space

    Lohmann, Frederieke; Allenspach, Stephan; Atz, Kenneth et al.

    Mol Inform · 2024 · English · PubMed Central

    Interpretability and reliability of deep learning models are important for computer‐based drug discovery. Aiming to understand feature perception by such a model, we investigate a graph neural network for affinity prediction of protein‐ligand complexes. We assess a latent representation of ligand…

  6. Journal Article Full text

    Accelerating compound synthesis in drug discovery: the role of digitalisation and automation

    Nippa, David F.; Boddy, Alexander J.; Atz, Kenneth et al.

    RSC Med Chem · 2025 · English · PubMed Central

    The Design-Make-Test-Analyse (DMTA) cycle relies on efficient compound synthesis, yet the synthesis (“Make”) process remains a significant bottleneck, especially for complex molecules. This opinion letter explores how digitalisation and automation are accelerating the entire synthesis process. It…

  7. Journal Article Full text

    Combining generative artificial intelligence and on-chip synthesis for de novo drug design

    Grisoni, Francesca; Huisman, Berend J. H.; Button, Alexander L. et al.

    Sci Adv · 2021 · English · PubMed Central

    Automating the molecular design-make-test-analyze cycle accelerates hit and lead finding for drug discovery. Using deep learning for molecular design and a microfluidics platform for on-chip chemical synthesis, liver X receptor (LXR) agonists were generated from scratch. The computational pipeline…

  8. Journal Article Full text

    Combining de novo molecular design with semiempirical protein–ligand binding free energy calculation

    Iff, Michael; Atz, Kenneth; Isert, Clemens et al.

    RSC Adv · 2024 · English · PubMed Central

    Semi-empirical quantum chemistry methods estimate the binding free energies of protein–ligand complexes. We present an integrated approach combining the GFN2-xTB method with de novo design for the generation and evaluation of potential inhibitors of acetylcholinesterase (AChE). We employed chemical…

  9. Journal Article Full text

    Simple User‐Friendly Reaction Format

    Nippa, David F.; Müller, Alex T.; Atz, Kenneth et al.

    Mol Inform · 2025 · English · PubMed Central

    Utilizing the growing wealth of chemical reaction data can boost synthesis planning and increase success rates. Yet, the effectiveness of machine learning tools for retrosynthesis planning and forward reaction prediction relies on accessible, well‐curated data presented in a structured format…

  10. Journal Article Full text

    Leveraging molecular structure and bioactivity with chemical language models for de novo drug design

    Moret, Michael; Pachon Angona, Irene; Cotos, Leandro et al.

    Nat Commun · 2023 · English · PubMed Central

    Generative chemical language models (CLMs) can be used for de novo molecular structure generation by learning from a textual representation of molecules. Here, we show that hybrid CLMs can additionally leverage the bioactivity information available for the training compounds. To computationally…

  11. Journal Article Full text

    G–PLIP: Knowledge graph neural network for structure-free protein–ligand bioactivity prediction

    Crouzet, Simon J.; Lieberherr, Anja Maria; Atz, Kenneth et al.

    Comput Struct Biotechnol J · 2024 · English · PubMed Central

    Protein–ligand interactions (PLIs) determine the efficacy and safety profiles of small molecule drugs. Existing methods rely on either structural information or resource-intensive computations to predict PLI, casting doubt on whether it is possible to perform structure-free PLI predictions at low…

  12. Journal Article Full text

    Geometric deep learning-guided Suzuki reaction conditions assessment for applications in medicinal chemistry

    Atz, Kenneth; Nippa, David F.; Müller, Alex T. et al.

    RSC Med Chem · 2024 · English · PubMed Central

    Suzuki cross-coupling reactions are considered a valuable tool for constructing carbon–carbon bonds in small molecule drug discovery. However, the synthesis of chemical matter often represents a time-consuming and labour-intensive bottleneck. We demonstrate how machine learning methods trained on…

  13. Journal Article Full text

    Identifying opportunities for late-stage C-H alkylation with high-throughput experimentation and in silico reaction screening

    Nippa, David F.; Atz, Kenneth; Müller, Alex T. et al.

    Commun Chem · 2023 · English · PubMed Central

    Enhancing the properties of advanced drug candidates is aided by the direct incorporation of specific chemical groups, avoiding the need to construct the entire compound from the ground up. Nevertheless, their chemical intricacy often poses challenges in predicting reactivity for C-H activation…

  14. Journal Article Full text

    Enabling late-stage drug diversification by high-throughput experimentation with geometric deep learning

    Nippa, David F.; Atz, Kenneth; Hohler, Remo et al.

    Nat Chem · 2023 · English · PubMed Central

    Late-stage functionalization is an economical approach to optimize the properties of drug candidates. However, the chemical complexity of drug molecules often makes late-stage diversification challenging. To address this problem, a late-stage functionalization platform based on geometric deep…

  15. Journal Article Full text

    Prospective de novo drug design with deep interactome learning

    Atz, Kenneth; Cotos, Leandro; Isert, Clemens et al.

    Nat Commun · 2024 · English · PubMed Central

    De novo drug design aims to generate molecules from scratch that possess specific chemical and pharmacological properties. We present a computational approach utilizing interactome-based deep learning for ligand- and structure-based generation of drug-like molecules. This method capitalizes on the…

  16. Journal Article Full text

    Translational molecular imaging and drug development in multiple sclerosis

    Tay, Daniel; Ahmed, Hazem; Dawoud, Alyaa et al.

    Theranostics · 2026 · English · PubMed Central

    Multiple sclerosis (MS) is a chronic inflammatory neurodegenerative disorder that typically affects young adults and is primarily characterized by demyelinating lesions in the central nervous system (CNS). According to the Revised McDonald Criteria, the clinical diagnosis of MS can be established…

  17. Journal Article Full text

    Expediting hit-to-lead progression in drug discovery through reaction prediction and multi-dimensional optimization

    Nippa, David F.; Atz, Kenneth; Stenzhorn, Yannick et al.

    Nat Commun · 2025 · English · PubMed Central

    The rapid and economical synthesis of novel bioactive compounds remains a hurdle in drug discovery efforts. This study demonstrates an integrated medicinal chemistry workflow that effectively diversifies hit and lead structures, enabling an acceleration of the critical hit-to-lead optimization…

  18. Journal Article Full text

    Single-position ligand modifications tune CB(2)R activity by targeting the toggle switch

    Ganzoni, Rudolf L. Z.; Kosar, Miroslav; Han, Yongqi et al.

    Chem Sci · 2026 · English · PubMed Central

    Cannabinoid receptor type 2 (CB(2)R) is a prominent class A G protein-coupled receptor (GPCR) and is a therapeutic target of interest for inflammatory diseases, pain management, and neurodegenerative disorders. We report the development of ligands based on HU-308 that share a single central…

  19. Journal Article Full text

    Detection of cannabinoid receptor type 2 in native cells and zebrafish with a highly potent, cell-permeable fluorescent probe

    Gazzi, Thais; Brennecke, Benjamin; Atz, Kenneth et al.

    Chem Sci · 2022 · English · PubMed Central

    Despite its essential role in the (patho)physiology of several diseases, CB(2)R tissue expression profiles and signaling mechanisms are not yet fully understood. We report the development of a highly potent, fluorescent CB(2)R agonist probe employing structure-based reverse design. It commences…